Marc P. Bonaca

2 weeks ago | ajmc.com | Giuliana Grossi |Christian C. Ruff |John B. Buse |Marc P. Bonaca |Marc Humbert |Jawad Haider Butt | +1 more

At the American College of Cardiology Annual Scientific Session (ACC.25), experts shared groundbreaking research poised to reshape cardiovascular care—particularly for women and patients with complex cardiometabolic conditions.

3 weeks ago | ajmc.com | Giuliana Grossi |Marc P. Bonaca

With weekly semaglutide treatment, patients with peripheral artery disease (PAD) and type 2 diabetes exhibited improved functional capacity when compared with placebo. The latest findings from the phase 3b, randomized, placebo-controlled, double-blind STRIDE trial (NCT04560998) were presented at the American College of Cardiology 2025 Annual Scientific Session.

3 weeks ago | healio.com | Erik Swain |Richard Smith |Marc P. Bonaca

• Ozempic improved walking distance in patients with diabetes and peripheral artery disease at 1 year. • An exploratory analysis suggested Ozempic reduced risk for major limb events and mortality. CHICAGO — Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, according to data from the STRIDE trial presented at the American College of Cardiology Scientific Session. Marc P.

Nov 28, 2024 | radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Marc P. Bonaca |Filippo L Gurgoglione

AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD). Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).

Nov 28, 2024 | radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Stephen Nicholls |Marc P. Bonaca

AHA Conference 2024 -  BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management. Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).